Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.

Feiyu ZhangMacarena FerreroNing DongGiuseppe D'Auria Mariana Reyes-Prieto Alejandro Herreros-Pomares Silvia Calabuig-FariñasElena DuréndezFrancisco AparisiAna BlascoClara GarcíaCarlos CampsEloísa Jantus-LewintreRafael Sirera

Published in: Cancers (2021)

Our results corroborate the relation between the baseline gut microbiota composition and ICB clinical outcomes in advanced NSCLC patients, and provide novel potential predictive and prognostic biomarkers for immunotherapy in NSCLC.

Keyphrases

small cell lung cancer
end stage renal disease
ejection fraction
newly diagnosed
advanced non small cell lung cancer
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
risk assessment
bone marrow
mesenchymal stem cells
brain metastases
replacement therapy